IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CICARDI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.733
NA - Nord America 8.591
AS - Asia 4.124
SA - Sud America 187
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 23
AF - Africa 21
Totale 24.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.354
GB - Regno Unito 5.423
CN - Cina 1.843
IT - Italia 1.352
DE - Germania 1.257
SE - Svezia 1.075
SG - Singapore 643
RU - Federazione Russa 505
TR - Turchia 441
IE - Irlanda 420
KR - Corea 398
UA - Ucraina 348
FR - Francia 304
IN - India 298
NL - Olanda 240
FI - Finlandia 228
CA - Canada 198
EU - Europa 190
VN - Vietnam 136
ES - Italia 102
CO - Colombia 101
DK - Danimarca 90
PL - Polonia 84
HK - Hong Kong 80
GR - Grecia 79
JP - Giappone 78
ID - Indonesia 71
BE - Belgio 65
BR - Brasile 38
MX - Messico 32
RO - Romania 32
AR - Argentina 27
TW - Taiwan 24
UZ - Uzbekistan 23
AU - Australia 22
PT - Portogallo 22
IR - Iran 21
CZ - Repubblica Ceca 19
BG - Bulgaria 17
IL - Israele 17
CH - Svizzera 16
AT - Austria 15
NZ - Nuova Zelanda 15
TH - Thailandia 15
CL - Cile 13
AE - Emirati Arabi Uniti 9
HU - Ungheria 9
HR - Croazia 7
PH - Filippine 6
PE - Perù 5
SC - Seychelles 5
YE - Yemen 5
MT - Malta 4
MY - Malesia 4
NO - Norvegia 4
ZA - Sudafrica 4
AP - ???statistics.table.value.countryCode.AP??? 3
KE - Kenya 3
RS - Serbia 3
SI - Slovenia 3
AM - Armenia 2
EC - Ecuador 2
EG - Egitto 2
GE - Georgia 2
GT - Guatemala 2
LB - Libano 2
LT - Lituania 2
LV - Lettonia 2
NG - Nigeria 2
SA - Arabia Saudita 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
CU - Cuba 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
FK - Isole Falkland (Malvinas) 1
IQ - Iraq 1
IS - Islanda 1
JO - Giordania 1
MA - Marocco 1
MD - Moldavia 1
MQ - Martinica 1
PA - Panama 1
PR - Porto Rico 1
QA - Qatar 1
SD - Sudan 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 24.886
Salva come PNG Salva come JPEG
Città #
Southend 4.913
Chandler 1.058
Seattle 674
Milan 585
Wilmington 534
Princeton 508
Fairfield 445
Singapore 407
Beijing 405
Dublin 405
Ashburn 378
Ann Arbor 328
Woodbridge 308
Houston 264
Jacksonville 264
Redmond 244
Nanjing 213
Redwood City 205
Dearborn 204
Mountain View 181
Somerville 168
Des Moines 167
New York 153
Sakarya 150
Bengaluru 147
Boardman 137
Cambridge 133
Toronto 112
Jinan 108
Andover 107
Serra 106
Bogotá 98
Shenyang 94
Nanchang 80
Dong Ket 77
Guangzhou 77
Athens 72
Saint Petersburg 69
Shanghai 69
Warsaw 68
Brussels 61
Hebei 55
Phoenix 55
Turin 51
Helsinki 50
Tianjin 50
Changsha 49
Duncan 49
Zhengzhou 48
London 47
Santa Clara 47
Berlin 45
Hong Kong 45
Fremont 43
San Diego 42
Putian 37
Ottawa 36
Sunnyvale 36
Jakarta 34
Jiaxing 33
Odernheim 33
Bitonto 32
Frankfurt am Main 32
Wuhan 32
Fuzhou 31
Eitensheim 30
Lexington 29
Grafing 28
Chicago 27
Ningbo 26
Silver Spring 26
Hangzhou 25
Hanover 25
Hefei 25
Roxbury 25
Seoul 25
Tokyo 25
Los Angeles 24
Barcelona 23
Philadelphia 23
Chengdu 22
Falls Church 22
Pisa 21
Taizhou 21
Buenos Aires 20
Haikou 20
Hamburg 20
Istanbul 20
Kiez 20
Lanzhou 20
Pune 20
Madrid 19
Kunming 18
Central District 17
Geisenheim 17
São Paulo 16
Verona 15
Washington 15
Nuremberg 14
Pskov 14
Totale 16.545
Salva come PNG Salva come JPEG
Nome #
Canadian hereditary angioedema guideline 585
Current and emerging biologics for the treatment of hereditary angioedema 490
Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema 435
The central role of endothelium in hereditary angioedema due to C1 inhibitor deficiency 377
Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency 315
Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema 266
Remittent C1-inhibitor deficiency due to Arg378Cys mutation 258
Profile of infective endocarditis observed from 2003 - 2010 in a single center in Italy 249
Inhibiting plasma kallikrein for hereditary angioedema prophylaxis 249
Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema Attacks : a Randomized Clinical Trial 227
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 221
Intermittent C1-Inhibitor Deficiency Associated with Recessive Inheritance: Functional and Structural Insight 215
High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibtor deficiency 211
A transcriptomics study of hereditary angioedema attacks 207
Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema 203
Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema 195
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks 189
Molecular mechanism for the pathogenicity of the human C1-inhibitor Arg378Cys variant 184
Consumption of C4b-binding protein (C4BP) during in vivo activation of the classical complement pathway 180
Structural and functional characterization of mutations in C1-ihn responsible for hereditary angioedema 176
Gene regulation in the pathogenesis of angioedema due to inherited c1 inhibitor deficiency (hereditary angioedema) 174
Hereditary angioedema: Assessing the hypothesis for underlying autonomic dysfunction 174
Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor 171
Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema : functional and structural correlates 171
Angioedema without urticaria : a large clinical survey 170
Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients 162
Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer 161
Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies 160
Effect of mutations within the coding region of C1-INH gene on protein function in families with HAE 159
Ongoing contact activation in patients with hereditary angioedema 157
Effects of mutations within the coding region of C1-INH gene on disease manifestation and protein function in families with HAE 156
Mechanisms of C1-inhibitor deficiency 156
Angioedema da ACE-inibitori: risultati dopo il passaggio ad una diversa terapia antiipertensiva 155
Successful resolution of bowel obstruction in a patient with hereditary angioedema 154
Hereditary and acquired angioedema : problems and progress : proceedings of the third C1 esterase inhibitor deficiency workshop and beyond 152
C1-inhibitor deficiency and angioedema : molecular mechanisms and clinical progress 150
Use of C1 inhibitor concentrate for treatment of angioedema attacks in patients with C1 inhibitor deficiency : survey of 1102 infusions in 503 patients 150
Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C 149
Pathogenetic and clinical aspects of C1-inhibitor deficiency 148
Angioedema and angiotensin-converting enzyme inhibitor use : results after switching to a different antihypertensive therapy 144
Gene regulation in the pathogenesis of inherited C1-inhibitor deficiency (Hereditary Angioedema) 144
Angioedema associated with angiotensin-converting enzyme inhibitor use : outcome after switching to a different treatment 143
Haemostasis contact system and fibrinolysis in hereditary angioedema (C1-inhibitor deficiency) 143
Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency 143
Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies 142
C1 inhibitor function and anti-C1 inhibitor autoantibodies in patients with HIV type 1 infection 141
Activation of the contact system and fibrinolysis in autoimmune acquired angioedema : a rationale for prophylactic use of tranexamic acid 141
A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy 141
Cardiopulmonary by-pass in a patient with acquired C1 inhibitor deficiency 140
Acquired angioedema 140
Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator 140
Activation of the coagulation cascade in C1- inhibitor deficiencies 139
Acquired C1 esterase inhibitor deficiency in two patients presenting with a lupus-like syndrome and anticardiolipin antibodies 138
C1 inhibitor : molecular and clinical aspects 138
Non neutralizing antibodies to tissue type plasminogen activator in serum of acute myocardial infarction patients treated with the recombinant protein 138
Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate 138
Identification of variables causing different clinical expression of inherited c1-inh deficiency (hereditary angioedema) 137
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema 137
Identification of variables causing different clinical expression of inherited c1-inh deficiency (hereditary angioedema) 135
Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema 134
Angioedema due to angiotensin-converting enzyme inhibitors 134
Acquired deficiency of the inhibitor of the first complement component : presentation, diagnosis, course, and conventional management 134
Idiopathic nonhistaminergic angioedema 132
Bradykinin and the pathophysiology of angioedema 131
Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema 131
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly 131
Autoimmune C1 inhibitor deficiency : report of eight patients 130
Catabolism of C1 inhibitor influences the response to replacement therapy in hereditary angioedema 130
Activation of blood coagulation in chronic urticaria : pathophysiological and clinical implications by Dr. Massimo Cugno et al. 129
Hepatic function and fibrinolysis in patients with hereditary angioedemaundergoing long-term treatment with tranexamic acid 129
The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema 128
Lymphoproliferative disease and acquired C1 inhibitor deficiency 125
Hereditary angioedema: an appraisal of 104 cases 125
Does acquired angioedema increase the risk of surgery with cardiopulmonary bypass? 124
Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency 123
Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice 123
Angioedema without urticaria in 929 Italian patients : proposal for a diagnostic and therapeutic approach 122
Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it 122
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: Design of the HELP study extension 121
Clinical and pathological findings of a fatal systemic capillary leak syndrome (Clarkson Disease) 119
Natural history and clinical impact of cryoglobulins in chronic hepatitis C : 10-year prospective study of 343 patients 116
Side effects of long-term prophylaxis with attenuated-androgens in hereditary angioedema : comparison between treated and non-treated patients 116
The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema 116
Costs and effects of on-demand treatment of hereditary angioedema in Italy : a prospective cohort study of 167 patients 116
A SERPING1 variant that causes C1-inhibitor deficiency without hereditary angioedema 116
Established and new treatments for hereditary angioedema : an update 115
Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angioedema 115
C1 inhibitor gene expression in patients with hereditary angioedema : quantitative evaluation by means of real-time RT-PCR 115
Dental experience and self-perceived dental care needs of patients with angioedema 115
C1-inhibitor concentrate for treatment of hereditary angioedema 115
A hinge region mutation in C1-inhibitor (Ala436-->Thr) results innonsubstrate-like behavior and in polymerization of the molecule 115
Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema 115
Emotional processes and stress in children affected by hereditary angioedema with C1-inhibitor deficiency : a multicenter, prospective study 115
C1-inhibitor deficiency and angioedema 114
Plasmatic markers of acute attack in patients with angioedemadue to C1 inhibitor deficiency 114
Angioedema due to acquired C1-inhibitor deficiency : a bridging condition between autoimmunity and lymphoproliferation 113
Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency 112
A simple endocrinological cause of a complex cardiovascular picture 112
Studies of complement activation in ARDS patients treated by long-term extracorporeal CO2 removal 111
Cardioprotective effect of C1-inhibitor 110
Totale 16.226
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.937
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.937
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.094 0 0 131 228 231 375 350 243 682 478 218 158
2020/20213.650 284 280 263 129 320 302 258 312 306 205 660 331
2021/20222.675 255 120 119 168 138 161 244 211 270 243 244 502
2022/20233.381 457 378 310 450 313 670 58 190 330 43 138 44
2023/20241.855 62 166 93 106 426 237 65 79 41 100 219 261
2024/2025736 202 453 81 0 0 0 0 0 0 0 0 0
Totale 26.406